A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Clinical trial NCT01515306 · COMPLETED

Trial details

NCT number: NCT01515306
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Malignant Solid Tumor

Start date: 2012-07-19
Primary completion: 2013-03-20
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.